Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Qualigen Therapeutics, Inc. (QLGN : NSDQ)

• Company Description    Qualigen Therapeutics Inc. is a biotechnology company. It is focused on developing products for the treatment and testing of cancer and infectious diseases. The company's product pipeline consist AS1411 and Gold Nanoparticle ALAN, RAS-F3 and STARS(TM) blood cleansing system, which are in clinical stage. Qualigen Therapeutics Inc., formerly known as Ritter Pharmaceuticals Inc., is based in CA, United States. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $3.52 Daily Weekly Monthly 20 Day Moving Average: 14,631 shares Shares Outstanding: 1.64 (millions) Market Capitalization: $5.76 (millions) Beta: 0.03 52 Week High: $29.44 52 Week Low: $2.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -7.90% -11.35% 12 Week 8.64% -8.62% Year To Date -16.39% -21.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5857 Owens Avenue Suite 300 - CARLSBAD,CA 92008 USA ph: 760-452-8111 fax: 760-918-9127 ir@qlgntx.com http://www.qlgntx.com

• General Corporate Information    Officers Kevin Richardson - Chief Executive Officer; Chief Financial Officer a Campbell Becher - Director Braeden Lichti - Director Robert B. Lim - Director Cody Price - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 74754R301 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/24 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 1.64 Most Recent Split Date: 11.00 (0.02:1) Beta: 0.03 Market Capitalization: $5.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 85.31% vs. Previous Quarter: 53.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 2.33 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 2.33 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - -4.12 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©